Genmab Statistics
Total Valuation
Genmab has a market cap or net worth of $12.78 billion. The enterprise value is $9.72 billion.
| Market Cap | 12.78B |
| Enterprise Value | 9.72B |
Important Dates
The next confirmed earnings date is Thursday, May 8, 2025.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genmab has 63.54 million shares outstanding. The number of shares has decreased by -1.95% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 63.54M |
| Shares Change (YoY) | -1.95% |
| Shares Change (QoQ) | +0.39% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 61.62M |
Valuation Ratios
The trailing PE ratio is 11.74 and the forward PE ratio is 12.88.
| PE Ratio | 11.74 |
| Forward PE | 12.88 |
| PS Ratio | 4.28 |
| Forward PS | 0.51 |
| PB Ratio | 2.51 |
| P/TBV Ratio | 4.22 |
| P/FCF Ratio | 11.07 |
| P/OCF Ratio | 11.85 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.48, with an EV/FCF ratio of 8.42.
| EV / Earnings | 8.93 |
| EV / Sales | 3.25 |
| EV / EBITDA | 9.48 |
| EV / EBIT | 9.90 |
| EV / FCF | 8.42 |
Financial Position
The company has a current ratio of 5.25, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.25 |
| Quick Ratio | 5.24 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | 0.12 |
| Interest Coverage | 58.99 |
Financial Efficiency
Return on equity (ROE) is 22.97% and return on invested capital (ROIC) is 12.62%.
| Return on Equity (ROE) | 22.97% |
| Return on Assets (ROA) | 10.91% |
| Return on Invested Capital (ROIC) | 12.62% |
| Return on Capital Employed (ROCE) | 17.48% |
| Revenue Per Employee | $1.12M |
| Profits Per Employee | $406,617 |
| Employee Count | 2,678 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 16.55 |
Taxes
In the past 12 months, Genmab has paid $183.25 million in taxes.
| Income Tax | 183.25M |
| Effective Tax Rate | 14.40% |
Stock Price Statistics
The stock price has decreased by -27.68% in the last 52 weeks. The beta is 0.96, so Genmab's price volatility has been similar to the market average.
| Beta (5Y) | 0.96 |
| 52-Week Price Change | -27.68% |
| 50-Day Moving Average | 20.62 |
| 200-Day Moving Average | 22.86 |
| Relative Strength Index (RSI) | 57.95 |
| Average Volume (20 Days) | 1,580,037 |
Short Selling Information
The latest short interest is 2.15 million, so 0.34% of the outstanding shares have been sold short.
| Short Interest | 2.15M |
| Short Previous Month | 3.06M |
| Short % of Shares Out | 0.34% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.44 |
Income Statement
In the last 12 months, Genmab had revenue of $2.99 billion and earned $1.09 billion in profits. Earnings per share was $16.85.
| Revenue | 2.99B |
| Gross Profit | 2.85B |
| Operating Income | 982.72M |
| Pretax Income | n/a |
| Net Income | 1.09B |
| EBITDA | 1.03B |
| EBIT | 982.72M |
| Earnings Per Share (EPS) | $16.85 |
Balance Sheet
The company has $2.93 billion in cash and $142.85 million in debt, giving a net cash position of $2.79 billion or $43.85 per share.
| Cash & Cash Equivalents | 2.93B |
| Total Debt | 142.85M |
| Net Cash | 2.79B |
| Net Cash Per Share | $43.85 |
| Equity (Book Value) | 5.09B |
| Book Value Per Share | 80.18 |
| Working Capital | 3.13B |
Cash Flow
In the last 12 months, operating cash flow was $1.08 billion and capital expenditures -$25.96 million, giving a free cash flow of $1.15 billion.
| Operating Cash Flow | 1.08B |
| Capital Expenditures | -25.96M |
| Free Cash Flow | 1.15B |
| FCF Per Share | $18.17 |
Margins
Gross margin is 95.42%, with operating and profit margins of 32.89% and 36.44%.
| Gross Margin | 95.42% |
| Operating Margin | 32.89% |
| Pretax Margin | 42.57% |
| Profit Margin | 36.44% |
| EBITDA Margin | 34.33% |
| EBIT Margin | 32.89% |
| FCF Margin | 38.63% |
Dividends & Yields
Genmab does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 1.95% |
| Shareholder Yield | 1.95% |
| Earnings Yield | 8.52% |
| FCF Yield | 9.03% |
Analyst Forecast
The average price target for Genmab is $39.17, which is 90.24% higher than the current price. The consensus rating is "Buy".
| Price Target | $39.17 |
| Price Target Difference | 90.24% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (5Y) | 11.89% |
| EPS Growth Forecast (5Y) | 7.41% |
Stock Splits
The last stock split was on May 1, 2018. It was a forward split with a ratio of 5:1.
| Last Split Date | May 1, 2018 |
| Split Type | Forward |
| Split Ratio | 5:1 |
Scores
Genmab has an Altman Z-Score of 10.02 and a Piotroski F-Score of 4.
| Altman Z-Score | 10.02 |
| Piotroski F-Score | 4 |